Acute Respiratory Distress Syndrome (ARDS) — Mechanism

1. Triggers and Initiating Insults

2. Core Pathogenesis — The Alveolar-Capillary Barrier

Step-by-step sequence:

A. Endothelial Activation (Early Key Event)

• The trigger (sepsis, trauma, aspiration, etc.) produces either direct pneumocyte injury or circulating inflammatory mediators (LPS, cytokines, DAMPs).
• Resident alveolar macrophages sense pneumocyte injury and secrete TNF-α, IL-1β, IL-8, which act on the adjacent pulmonary microvascular endothelium.
• Alternatively, circulating mediators directly activate endothelial cells.
• Activated endothelium upregulates adhesion molecules (ICAM-1, E-selectin), procoagulant proteins, and chemokines.

B. Neutrophil Sequestration and Degranulation

• Neutrophils adhere to activated endothelium and migrate into the interstitium and alveoli.
• Once there, they degranulate, releasing:
  • Proteases (elastase, metalloproteinases) — digest the basement membrane and extracellular matrix
  • Reactive oxygen species (ROS) — directly injure pneumocytes and endothelial cells
  • Cytokines — amplify the inflammatory loop
  • Neutrophil extracellular traps (NETs) — contribute directly to lung tissue damage

C. Increased Alveolar-Capillary Permeability

• Injury to both endothelium (disrupting tight junctions) and alveolar epithelium (necrosis of type I pneumocytes) breaks down the alveolar-capillary membrane.
• Protein-rich, exudative fluid pours into the interstitium and then into alveolar spaces — noncardiogenic pulmonary edema.
• Unlike hydrostatic (cardiogenic) edema, this fluid has high protein content because the permeability barrier is structurally disrupted, not just pressure-overloaded.

D. Surfactant Dysfunction

• Type II pneumocytes (the source of surfactant) are damaged by:
  • Direct injury from the insult
  • Inflammatory mediators (phospholipase A₂ from activated macrophages/neutrophils degrades surfactant phospholipids)
  • Inhibition by leaked plasma proteins in the alveolar fluid
• Loss of surfactant → increased alveolar surface tension → diffuse alveolar collapse (atelectasis) → worsening hypoxemia.

E. Coagulation Activation

• The inflammatory cascade activates the coagulation system within the alveolar space.
• Fibrin deposition in capillaries and alveoli contributes to microvascular thrombosis, impaired perfusion, and dead space.
• Together with cellular debris, this inspissated fibrin forms the pathognomonic hyaline membranes lining the alveolar walls.

F. The Inflammatory-Endothelial Feedback Loop

• Neutrophil-derived mediators cause further endothelial damage → more permeability → more neutrophil recruitment. This self-amplifying loop is the core engine of progressive ARDS.
• Angiopoietin-2 (a destabilizer of endothelial integrity) is elevated in ARDS and promotes vascular leak; Angiopoietin-1 (stabilizing) is reduced. This imbalance is an active research target.

3. Pathologic Phases (Diffuse Alveolar Damage — DAD)

4. Physiologic Consequences

5. Cellular Mechanisms Summary (Inflammatory Cascade)

• M1 macrophages (activated via TLR/PRR) → produce PICs (TNF-α, IL-1, IL-6)
• Endothelial cell activation → breakdown of vascular barrier
• Th17 upregulation / T-regulatory cell suppression → loss of anti-inflammatory balance (↓IL-10, ↓TGF-β)
• Platelet-neutrophil complexes → release ROS, myeloperoxidase (MPO), NETs → necroptosis/pyroptosis
• End result: increased cell permeability + diffuse alveolar damage + fibrin-rich hyaline membranes

6. Resolution vs. Fibrosis

• Macrophages clear alveolar debris and release TGF-β and PDGF → fibroblast proliferation and collagen synthesis.
• Type II pneumocytes proliferate to replace destroyed type I cells (type II → type I differentiation).
• Endothelial regeneration occurs from surviving capillary endothelium.
• In a subset, this fibroproliferative phase leads to permanent pulmonary fibrosis and long-term impairment.

7. Berlin Definition (Clinical Anchor)